摘要
目的 :观察糖尿病周围神经病变患者的ET、TXB2 、PGF1α的改变及西洛他唑 (Cilostazol)和甲钴胺联合治疗糖尿病周围神经病变 (DPN)的疗效和对以上三指标的影响 ,以证明糖尿病周围神经病变微血管机制学说。方法 :将 30例正常中老年人为对照组 ,76例DPN患者随机分为甲钴胺组和西洛他唑、甲钴胺联合用药组 ,共三组。测定三组治疗前及治疗组经 12周药物治疗后的ET、TXB2 、PGF1α值并进行比较 ,通过临床症状和神经传导速度的观察对其治疗效果进行比较。结果 :甲钴胺组和联合用药组 (二组DPN组 )的ET、TXB2 明显高于对照组 (P <0 0 5 ) ,PGF1α值明显低于对照组 (P <0 0 5 ) ;联合治疗组治疗前后ET、TXB2 、PGF1α值有显著差异 (P <0 0 5 ) ,甲钴胺组差异不明显 (P >0 0 5 ) ;联合治疗组DPN症状、神经传导速度改善明显好于甲钴胺治疗组 (P <0 0 5 )。结论 :糖尿病周围神经病变微血管功能存在障碍 ,通过药物干预能改善DPN的微血管功能和临床症状 ,故微血管障碍可能为DPN发病机制之一。
Objective To test the possible role of micorvascular lesions in the development of DPN through investigation of changes of plasma ET, TXB 2, PGF 1α levels and treatment effect with use of cilostazol and mecobalamin in these patients. Methods Plasma ET, TXB 2, PGF 1α levels were measured in: ① 36 DPN patients before and after trentment with mecobalamin only for 12 weeks ② 36 patients before and after treatment with mecobalamin plus cilostazol for 12 weeks and ③ 30 controls. Clinical symptoms and nerve conduction velocity were evaluated. Results In DPN patients, the plasma ET, TXB 2 levels were significantly higher and plasma PGF 1α levels were significantly lower than those in the controls (P<0.05). With combined treatment, the differences of these value before and after treatment were significant (P<0.05) but not so in the patients treated with mecobalamin only (P>0.05). Improvement of clinical symptom and nerve conduction velocity were also much better with combined treatment (P<0.05). Conclusion There are microvasculan damage and dysfuction in patients with DPN, which may be ameliorated with drags. Microvascular lesions play important role in the development of DPN.
出处
《放射免疫学杂志》
CAS
2004年第3期171-173,共3页
Journal of Radioimmanology
